FRONTIERS IN BIOSCIENCE;

DATA FORM FOR CANCER STAGING - MELANOMA





Form # 785-1-036

CLIN PATH DEFINITIONS
    PRIMARY TUMOR (PT)

pTX Primary tumor cannot be assessed

pT0 No evidence of primary tumor

pTis Melanoma in situ (atypical melanocytic hyperplasia, severe melanocytic dysplasia, not an invasive lesion (Clark's Level I)

pT1 Tumor 0.75 mm or less in thickness and invades the papillary dermis (Clark's Level II)

pT2 Tumor more than 0.75 mm but not more than 1.5 mm in thickness and/or invades to papillary-reticular dermal interface (Clark's Level III)

pT3 Tumor more than 1.5 mm but not more than 4 mm in thickness and/or invades the reticular dermis (Clark's V)Level I

  pT3a Tumor more than 1.5 mm but not more than 3 mm in thickness

  pT3b Tumor more than 3 mm but not more than 4 mm in thickness

pT4 Tumor more than 4 mm in thickness and/or invades the subcutaneous tissue (Clark's Level V) and/or satellite(s) within 2 cm of the primary tumor

  pT4a Tumor more than 4 mm in thickness and/or invades the subcutaneous tissue

  pT4b Satellite(s) within 2 cm of primary tumor
    LYMPH NODE (N)

NX Regional lymph nodes cannot be assessed

N0 No regional lymph node metastasis

N1 Metastasis 3 cm or less in greatest dimension in any regional lymph node(s)

N2 Metastasis more than 3 cm in greatest dimension in any regional lymph node(s) and/or in-transit metastasis

  N2a Metastasis more than 3 cm in greatest dimension in any regional lymph node(s)

  N2b In-transit metastasis

  N2c Both (N2a and N2b)
    DISTANT METASTASIS (M)

MX Presence of distant metastasis cannot be assessed

M0 No distant metastasis

M1 Distant metastasis

M1a   Metastasis in skin or subcutaneous tissue or lymph node(s) beyond the regional lymph nodes

M1b   Visceral metastasis

Pathologic Stage by: M.D. Date:

 CLIN PATH  STAGE GROUPING

0 Tis N0 M0

I T1 N0 M0
      T2 N0 M0

II T3 N0 M0
      T4 N0 M0

III Any T N1 M0
      Any T N2 M0

IV Any T Any N M1

Attending: M.D. Date:

THE FINAL STAGE GROUPING (CLINICAL & PATHOLOGICAL) IS THE RESPONSIBILITY OF THE ATTENDING PHYSICIAN.

Comments:

Patient Name: